Vivus (VVUS) expects a European panel to
advise against authorizing its obesity drug Qsiva despite the product
receiving FDA approval in July. The company expects a formal decision next
month, after which Vivus could appeal or resubmit its application if Qsiva is
rejected. Shares are -13.4% premarket.
More Stocks News
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com